September 18, 2020 07:05 ET | Source: OncXerna Therapeutics, Inc.
OncXernas RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients
Interim results from a Phase 2 trial of bavituximab with KEYTRUDA (pembrolizumab) demonstrates a 19% overall response rate (ORR)and 43% (3/7) ORR from an exploratory analysis in a biomarker-driven subgroup of advanced gastric cancer patients
OncXernas RNA-based biomarker panel predicts enhanced response in a Phase 1b trial of navicixizumab in late-stage ovarian cancer patients. Patients in thebiomarker positive panel achieved a 70% ORR, and excludedall who had progressive disease, compared with a 31% ORR for patients in the biomarker negativepanel
WALTHAM, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to predict patient responses for potentially first-in-class targeted oncology therapies, today announced new data and analyses from its lead clinical programs, bavituximab and navicixizumab. On the basis of these positive data, the company also announced its rebranding to OncXerna Therapeutics, Inc., a change that reinforces the companys focus on using its RNA-based approach to guide novel, targeted treatments to specific people with cancer.
With a deep understanding of the tumor microenvironment biology at the RNA-level through our novel biomarker panel, we aim to dramatically improve clinical outcomes by matching patients to therapies with a mechanism of action that targets that specific biology, said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. Todays results demonstrate a clear ability of our first panel to distinguish responders versus non-responders in our bavituximab and navicixizumab programs, and we are excited to deploy this approach in the next prospectively-defined trials that could support registration.
Interim results from Phase 2 (ONCG100) trial of bavituximab and KEYTRUDA
Trial design and background:
The Phase 2 (ONCG100) trial is a multicenter, open-label, single-arm global trial designed to assess the safety, tolerability, and antitumor activity of the investigational agent bavituximab, a chimeric monoclonal antibody that targets phosphatidylserine, in combination with KEYTRUDA, Mercks anti-PD-1 therapy, in patients with advanced gastric and gastroesophageal cancer who have progressed on or after at least one prior standard therapy. Bavituximab previously demonstrated clinical activity in a post-hoc subset analysis in patients with non-small cell lung cancer (NSCLC) who were given a PD-1 inhibitor following bavituximab treatment, suggesting that a treatment combination of bavituximab and a PD-1 inhibitor could generate similar activity in a prospective clinical trial. In addition to measuring safety and antitumor activity in this trial, OncXerna is deploying its proprietary RNA biomarker platform (TME Panel-1) to identify patients based on their response to treatment and the dominant biology of their tumor microenvironment with the potential to dramatically improve outcomes in the next, prospectively designed trial.
Approximately 80 patients in the U.S., United Kingdom, South Korea and Taiwan are planned for enrollment in two separate groups of patients: Checkpoint inhibitor-nave and checkpoint inhibitor-relapsed. The trial is continuing to enroll both groups with planned updates from all patients during the first half of 2021.
Interim results:
Interim results provided today, from the first 36 patients enrolled and with a post-baseline scan in the checkpoint inhibitor-nave group, include the following:
Next steps:
These data are being presented at the European Society for Molecular Oncology (ESMO) Virtual Congress 2020 taking place September 19-21, 2020.
OncXerna plans to conduct additional clinical trials designed to prospectively enrich for TME Panel-1 biomarker positive patients, as well as to explore additional solid tumor types.
OncXerna biomarker analysis from Phase 1b trial evaluating navicixizumab in ovarian cancer
Previously announced data and background:
OncXernas navicixizumab is a bispecific antibody designed to inhibit both Delta-like ligand 4 (DLL4) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (VEGF). Interim data from a Phase 1b dose escalation and expansion trial of navicixizumab plus paclitaxel in 44 platinum-resistant ovarian cancer patients who had failed more than two prior therapies and/or received prior Avastin (bevacizumab) therapy were presented virtually at the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting in May 2020. Treatment with navicixizumab and paclitaxel demonstrated an ORR of 43%in all patients, and 64% and 33% in bevacizumab-nave, and bevacizumab pre-treated patients, respectively. Treatment-related adverse events were manageable and included hypertension (58%), headache (29%), fatigue (26%) and pulmonary hypertension (18%).
Updated biomarker analyses and results:
Using its RNA-based biomarker TME Panel-1, OncXerna recently analyzed patient tissue samples obtained from 28 of the 44 patients from the Phase 1b trial. Results from this analysis revealed the following:
Next steps:
As a result of these analyses, OncXerna plans to conduct additional clinical trials designed to prospectively enrich for TME Panel-1 biomarker positive patients with ovarian cancer who are platinum-resistant and Avastin-experienced to support registration, as well as to explore additional solid tumor types.
About Bavituximab
Bavituximab is an investigational antibody that reverses immune suppression by inhibiting phosphatidylserine (PS) signaling and is currently in Phase 2 clinical trials to treat a specific subset of patients with advanced gastric cancer to improve their response to anti-PD-1 treatment. The mechanism of action of bavituximab is to block tumor immune suppression signaling from PS to multiple immune cell receptor families (e.g., TIMs and TAMs). The dominant biology targeted by bavituximab may be relevant for patients with many types of solid tumors whose immune systems are too suppressed to benefit from currently available immune oncology therapies. Our clinical trials currently combine bavituximab with KEYTRUDA to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors. Bavituximab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced gastric cancer.
About Navicixizumab
Navicixizumab is an investigational anti-DLL4/VEGF bispecific antibody that has demonstrated antitumor activity in patients who have progressed on Avastin (bevacizumab) in a Phase 1a/b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or prior treatment with Avastin. OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways. Navicixizumab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.
About OncXerna Therapeutics
OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the companys deep understanding of how to prospectively identify patients based on the dominant, RNA-based biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes. For more information on OncXerna, please visit oncxerna.com/
About OncXernas RNA-based Biomarker Platform
Existing precision medicines target only approximately 10% of cancersthose with gene mutations or oncogenic drivers for a small number of genes. Using its proprietary biomarker platform, OncXerna is leveraging the companys deep understanding of tumor biology at the RNA level to identify the dominant biology underlying a patients cancer. OncXernas first biomarker panel is specific to the tumor microenvironment (TME Panel-1). Initial results from TME Panel-1 reveal 4 different dominant biologies, demonstrating the presence of specific patient subgroups and their predictive value in responding to treatment. OncXerna is further optimizing the biomarker platforms tumor microenvironment panel through multiple research collaborations, including a collaboration with Moffitt Cancer Center.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Investor and Media Contact:
Ashley R. Robinson LifeSci Partners, LLC arr@lifesciadvisors.com
Read more here:
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics - GlobeNewswire
- Vascular Cell and Molecular Biology | Center for Vascular Biology | Weill Cornell ... - April 13th, 2018 [April 13th, 2018]
- APVBO-Asia Pacific Vascular Biology Organization Conference - April 18th, 2018 [April 18th, 2018]
- Vascular Biology Conferences | Vascular Surgery ... - May 5th, 2018 [May 5th, 2018]
- Vascular Discovery: From Genes to Medicine - May 7th, 2018 [May 7th, 2018]
- 2019 Vascular Cell Biology Conference GRC - May 26th, 2018 [May 26th, 2018]
- Biology 211: Taxonomy of Flowering Plants - June 7th, 2018 [June 7th, 2018]
- esm-evbo2019.org - Menu - July 27th, 2018 [July 27th, 2018]
- Vascular Biology | Pulmonary, Allergy, Sleep & Critical ... - November 16th, 2018 [November 16th, 2018]
- Lower vascular plant | biology | Britannica.com - November 18th, 2018 [November 18th, 2018]
- Vascular Biology - NAVBO - November 20th, 2018 [November 20th, 2018]
- 2019 Cerebral Vascular Biology Conference - cvent.com - November 21st, 2018 [November 21st, 2018]
- PPARs and Their Emerging Role in Vascular Biology ... - November 26th, 2018 [November 26th, 2018]
- Vascular Biology Chicago Medicine - November 30th, 2018 [November 30th, 2018]
- Vascular Biology | Society for Vascular Surgery - November 30th, 2018 [November 30th, 2018]
- Vascular Biology 2018 - NAVBO - December 19th, 2018 [December 19th, 2018]
- Vascular Biology 2019 - NAVBO - December 20th, 2018 [December 20th, 2018]
- Vascular Biology - January 22nd, 2019 [January 22nd, 2019]
- pvb2019.org Plant Vascular Biology Conference 2019 - January 31st, 2019 [January 31st, 2019]
- Plant Physiology | Basic Biology - March 12th, 2019 [March 12th, 2019]
- Awards - esm-evbo2019.org - April 23rd, 2019 [April 23rd, 2019]
- Medication and Exercise to Prevent Muscle Loss - Next Avenue - September 24th, 2019 [September 24th, 2019]
- A Snail as Fast as a Bullet, and Other Darwin-Defying Marvels - Discovery Institute - September 24th, 2019 [September 24th, 2019]
- Nature up close: Life in the Humboldt Penguin National Reserve - CBS News - September 24th, 2019 [September 24th, 2019]
- Oklahoma new hires and promotions announced - Oklahoman.com - September 24th, 2019 [September 24th, 2019]
- Quinn Capers IV, MD - TCTMD - September 24th, 2019 [September 24th, 2019]
- Cardiovascular Repair And Reconstruction Devices Market Global Industry Insights by Top Vendors, Growth, Revenue and Forecast Outlook 2019-2025 -... - September 26th, 2019 [September 26th, 2019]
- Four health projects at Boston Childrens Hospital that could help adults - The Boston Globe - September 30th, 2019 [September 30th, 2019]
- Research Officer/ Postdoctoral Researcher - The Conversation AU - October 16th, 2019 [October 16th, 2019]
- UNSW skin cancer researcher Levon Khachigian hit with string of retractions - ABC News - October 16th, 2019 [October 16th, 2019]
- Michal Wszola: We Expect to Transplant the Bioprinted Bionic Pancreas in Three to Five Years - 3DPrint.com - October 24th, 2019 [October 24th, 2019]
- 'The Blob': This mysterious 'smart' slime can solve puzzles and make decisions - CNBC - October 24th, 2019 [October 24th, 2019]
- University of Maryland and DOD collaborate to study Tick-borne Infections using 3-D models of human blood vessels - Outbreak News Today - November 19th, 2019 [November 19th, 2019]
- Submerged Vegetation Mirrors Coast's Health - Coastal Review Online - November 19th, 2019 [November 19th, 2019]
- Another health warning for e-cigarette users that has nothing to do with lung disease - MarketWatch - November 19th, 2019 [November 19th, 2019]
- E-Cigarettes Take a Dangerous Toll on Heart Health - DocWire News - November 19th, 2019 [November 19th, 2019]
- Vascular biology Department of Surgery College of ... - November 19th, 2019 [November 19th, 2019]
- US Nobel laureates tell us what they think about cancer research, moonshots, the dark side, funding, meritocracy, herd mentality, Trump, and joy - The... - November 21st, 2019 [November 21st, 2019]
- Growing Organs in the Lab: One Step Closer to Reality - BioSpace - November 21st, 2019 [November 21st, 2019]
- Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock - Business Wire - November 21st, 2019 [November 21st, 2019]
- Another Study Suggests E-cigarettes Hurt Heart Health More Than Regular Cigarettes - Science Times - November 21st, 2019 [November 21st, 2019]
- Cleveland Clinic awarded $12 million by NIH to study the link between gut microbes and heart disease - Crain's Cleveland Business - November 21st, 2019 [November 21st, 2019]
- JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD) - Yahoo Finance - November 27th, 2019 [November 27th, 2019]
- Germ-free lungs of newborn mice are partially protected against hyperoxia - The Mix - November 27th, 2019 [November 27th, 2019]
- Bethesda Health Physician Group Welcomes Fellowship-Trained Endocrine Surgeon Jessica L. Buicko, MD, to Its Team - The Boca Raton Tribune - November 27th, 2019 [November 27th, 2019]
- 9 Harvard researchers named AAAS Fellows Harvard - Harvard Gazette - November 27th, 2019 [November 27th, 2019]
- Top Technical Advances of 2019 - The Scientist - December 29th, 2019 [December 29th, 2019]
- Growing up Tyrannosaurus rex: Osteohistology refutes the pygmy Nanotyrannus and supports ontogenetic niche partitioning in juvenile Tyrannosaurus -... - January 2nd, 2020 [January 2nd, 2020]
- UCC currently taking applicants for 21 jobs with some incredible pay - Cork Beo - January 2nd, 2020 [January 2nd, 2020]
- Vascular Biology | Surgery Research | Michigan Medicine ... - January 2nd, 2020 [January 2nd, 2020]
- Sandy Bottom wetlands to receive protection for 'national ecological significance' - Citizen Times - January 14th, 2020 [January 14th, 2020]
- Why biotech is a boon for patients and investors - Spear's WMS - January 14th, 2020 [January 14th, 2020]
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related... - January 14th, 2020 [January 14th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 Dagoretti News - Dagoretti News - January 18th, 2020 [January 18th, 2020]
- Scientists revealed the oldest known scorpion on Earth - Tech Explorist - January 18th, 2020 [January 18th, 2020]
- How biology creates networks that are cheap, robust, and efficient - Penn: Office of University Communications - January 18th, 2020 [January 18th, 2020]
- Genome editing heralds new era of disease research, therapy - The Augusta Chronicle - January 18th, 2020 [January 18th, 2020]
- Research Fellow in Vascular Stem Cell Biology job with QUEENS UNIVERSITY BELFAST | 195527 - Times Higher Education (THE) - February 10th, 2020 [February 10th, 2020]
- More than skin deep: the latest innovation in 3D printing - Med-Tech Innovation - February 10th, 2020 [February 10th, 2020]
- Examining the link between menopause and heart disease risk - Medical News Bulletin - February 10th, 2020 [February 10th, 2020]
- Women Face an Increased Risk of Heart Disease With AgeRunning Can Help - runnersworld.com - February 12th, 2020 [February 12th, 2020]
- G-protein Coupled Receptor Market Competitive Research And Precise Outlook 2019 To 2025 - Galus Australis - February 15th, 2020 [February 15th, 2020]
- Valentine's Day Matters of the Heart, Biopharma-Style - BioSpace - February 15th, 2020 [February 15th, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Sharon - February 22nd, 2020 [February 22nd, 2020]
- UI at 150 & Beyond: 'The Quad was the best no matter what the weather' - Champaign/Urbana News-Gazette - February 22nd, 2020 [February 22nd, 2020]
- The Addicted Gardener: Environmental tidbits from around the world - Wicked Local Dedham - February 23rd, 2020 [February 23rd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Wareham - March 22nd, 2020 [March 22nd, 2020]
- 'Little Foot' skull reveals how this more than 3 million year old human ancestor lived - HeritageDaily - March 22nd, 2020 [March 22nd, 2020]
- It's Not Only About Neurons - The Good Men Project - March 22nd, 2020 [March 22nd, 2020]
- Who is Sir Patrick Vallance and what is his role in government during coronavirus outbreak? - The Scottish Sun - March 22nd, 2020 [March 22nd, 2020]
- University of Washington Pathology Professor Dies of COVID-19 - The Scientist - March 22nd, 2020 [March 22nd, 2020]
- THE ADDICTED GARDENER: Environmental tidbits from around the world - Wicked Local Rochester - March 23rd, 2020 [March 23rd, 2020]
- Ancient human ancestor 'Little Foot' probably lived in trees, new research finds - WBAP News/Talk - March 23rd, 2020 [March 23rd, 2020]
- Study shows similarity in anti-VEGF injection intervals for wet AMD - Ophthalmology Times - March 25th, 2020 [March 25th, 2020]
- aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform - BioSpace - March 25th, 2020 [March 25th, 2020]
- Health researchers find solution to life-threatening side effect - Mirage News - March 25th, 2020 [March 25th, 2020]
- European Vascular Biology Organisation | Advancing human ... - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Program | Boston Children's Hospital - March 25th, 2020 [March 25th, 2020]
- Vascular Biology Research Program | Johns Hopkins ... - March 25th, 2020 [March 25th, 2020]
- Anatomy of a heatwave: how Antarctica recorded a 20.75C day last month - The Conversation AU - April 1st, 2020 [April 1st, 2020]
- Who is Sir Patrick Vallance and is he speaking at todays government coronavirus press briefing? - The Sun - April 1st, 2020 [April 1st, 2020]